Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform
Silo Pharma (Nasdaq: SILO) has announced a strategic expansion into cryptocurrency treasury management, focusing on Bitcoin, Ethereum, and Solana. The company has appointed crypto infrastructure expert Corwin Yu as the first member of its new Crypto Advisory Board to spearhead this initiative.
The strategy includes opportunistic digital currency purchases and yield generation through staking, supported by newly acquired AI-powered market intelligence technology. Simultaneously, Silo Pharma continues its biopharmaceutical focus, with its PTSD drug SPC-15 approaching FDA IND application submission.
Silo Pharma (Nasdaq: SILO) ha annunciato un'espansione strategica nella gestione del tesoro in criptovalute, concentrandosi su Bitcoin, Ethereum e Solana. L'azienda ha nominato l'esperto di infrastrutture crypto Corwin Yu come primo membro del nuovo Crypto Advisory Board per guidare questa iniziativa.
La strategia prevede acquisti opportunistici di valute digitali e generazione di rendimenti tramite staking, supportati da una nuova tecnologia di intelligenza artificiale per l'analisi del mercato. Contemporaneamente, Silo Pharma mantiene il suo focus biofarmaceutico, con il farmaco per il PTSD SPC-15 che si avvicina alla presentazione della domanda IND alla FDA.
Silo Pharma (Nasdaq: SILO) ha anunciado una expansión estratégica en la gestión de tesorería en criptomonedas, enfocándose en Bitcoin, Ethereum y Solana. La compañía ha designado al experto en infraestructura cripto Corwin Yu como el primer miembro de su nuevo Crypto Advisory Board para liderar esta iniciativa.
La estrategia incluye compras oportunistas de monedas digitales y generación de rendimientos mediante staking, respaldada por una tecnología de inteligencia artificial para inteligencia de mercado recientemente adquirida. Simultáneamente, Silo Pharma continúa con su enfoque biofarmacéutico, con su medicamento para el TEPT SPC-15 próximo a la presentación de la solicitud IND ante la FDA.
Silo Pharma (나스닥: SILO)가 비트코인, 이더리움, 솔라나에 중점을 둔 암호화폐 자산 관리 분야로 전략적 확장을 발표했습니다. 회사는 이 이니셔티브를 이끌기 위해 암호화폐 인프라 전문가 코윈 유(Corwin Yu)를 새로운 암호화 자문위원회의 첫 멤버로 임명했습니다.
이 전략에는 기회주의적 디지털 화폐 매입과 스테이킹을 통한 수익 창출이 포함되며, 새로 도입한 AI 기반 시장 정보 기술의 지원을 받습니다. 동시에 Silo Pharma는 생명공학 분야에 집중하며, 외상 후 스트레스 장애(PTSD) 치료제 SPC-15의 FDA IND 신청 제출이 임박했습니다.
Silo Pharma (Nasdaq : SILO) a annoncé une expansion stratégique dans la gestion de trésorerie en cryptomonnaies, en se concentrant sur Bitcoin, Ethereum et Solana. La société a nommé l'expert en infrastructure crypto Corwin Yu comme premier membre de son nouveau Crypto Advisory Board pour piloter cette initiative.
La stratégie comprend des achats opportunistes de devises numériques et la génération de rendement via le staking, soutenue par une nouvelle technologie d'intelligence artificielle pour l'analyse de marché. Parallèlement, Silo Pharma poursuit son orientation biopharmaceutique, avec son médicament contre le PTSD SPC-15 qui approche la soumission de la demande IND à la FDA.
Silo Pharma (Nasdaq: SILO) hat eine strategische Erweiterung im Bereich der Kryptowährungs-Treasury-Verwaltung angekündigt, mit Fokus auf Bitcoin, Ethereum und Solana. Das Unternehmen hat den Krypto-Infrastruktur-Experten Corwin Yu als erstes Mitglied seines neuen Crypto Advisory Boards berufen, um diese Initiative zu leiten.
Die Strategie umfasst opportunistische Käufe digitaler Währungen und Ertragsgenerierung durch Staking, unterstützt durch neu erworbene KI-gestützte Marktanalyse-Technologie. Gleichzeitig bleibt Silo Pharma seinem biopharmazeutischen Fokus treu, wobei das PTSD-Medikament SPC-15 kurz vor der Einreichung des FDA IND-Antrags steht.
- Diversification into cryptocurrency treasury management with focus on leading digital assets
- Appointment of experienced crypto infrastructure expert Corwin Yu to lead strategy
- Acquisition of AI-powered market intelligence technology for informed decision-making
- Progress with PTSD drug SPC-15 nearing FDA IND application stage
- Potential volatility and risks associated with cryptocurrency investments
- Dependency on market conditions and available capital for strategy implementation
- Pending FDA approval for IND application creates regulatory uncertainty
Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration
SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), today announced the launch of a cryptocurrency treasury strategy which is expected to focus on leading digital assets, including Bitcoin, Ethereum, and Solana. The Company intends to make opportunistic purchases of digital currencies following launch and to leverage staking to generate yield while also focusing on capital preservation and token appreciation. Expanded implementation of this strategy is anticipated to be based on available capital and market conditions. Silo has appointed digital asset tech pioneer, Corwin Yu, as the first member of its newly formed Crypto Advisory Board to lead this new strategy. To further this initiative, Silo has recently acquired market intelligence technology powered by artificial intelligence, equipping the team with real-time insights to potentially drive smarter, faster decision-making.
“With the recent rise of successful cryptocurrency treasury allocations, and increasing capital inflows to digital assets, we believe there is an opportunity to potentially create and unlock long-term value for Silo’s stockholders, starting now,” said Silo CEO Eric Weisblum. “We believe that we are fortunate to appoint Corwin Yu as our lead strategic advisor and head of a newly formed three-member advisory board overseeing our crypto treasury strategy, with 2 other members to be appointed in the future.”
Corwin Yu is a senior technology and trading executive with over 20 years of experience building and managing mission-critical systems for institutional finance. Mr. Yu currently serves as Global Head of Digital Assets at fintech company TSImagine, and previously he was the founding Chief Technology Officer of MARKTS, one of the first institutional crypto trading platforms. In addition to these leadership roles, his prior experience spanned PIMCO, Credit Suisse, hedge funds and digital asset firms. As a proven leader in cryptocurrency trading infrastructure, fund management, and regulatory compliance, Mr. Yu has an extensive background in deploying scalable cloud-native platforms and overseeing cross-asset trading strategies. His track record includes founding and scaling digital asset trading platforms, managing global engineering and DevOps teams, and delivering secure and compliant crypto custody and treasury solutions.
“Alongside our launching of a digital asset treasury strategy, we remain deeply committed to our core biopharmaceutical enterprise focused on innovative therapeutics for underserved conditions,” Mr. Weisblum continued. “Our lead asset, PTSD drug SPC-15, is completing final studies before submitting an FDA investigational new drug (IND) application, and if such IND is approved we would look to commence a first-in-human Phase 1 clinical trial.”
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is Silo Pharma's (SILO) new cryptocurrency treasury strategy?
Who is Corwin Yu and what is his role at Silo Pharma?
How will Silo Pharma's crypto strategy affect its pharmaceutical business?
What is the status of Silo Pharma's PTSD drug SPC-15?
What technology will Silo Pharma use for its crypto treasury management?
